Hannah Zhong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Hannah Zhong has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Dani Ran Castillo
Department of Medical Oncology and Therapeutics Research, City of Hope, Duarte, CA
2 shared publications - Derek Tai
Loma Linda University Medical Center
2 shared publications - Gagandeep Brar
Department of Medical Oncology and Therapeutics Research, City of Hope, 1500 E Duarte Rd., Duarte, CA 91010, USA
2 shared publications - Kyung-Il John Kim
Department of Internal Medicine, Kaiser Permanente Fontana Medical Center, 9961 Sierra Ave., Fontana, CA 92335, USA
2 shared publications - Pranati Shah
Loma Linda University Medical Center, Internal Medicine, Loma Linda, CA
2 shared publications - Sofia Guzman
Department of Medical Oncology and Therapeutics Research, City of Hope, 1500 E Duarte Rd., Duarte, CA 91010, USA
2 shared publications
Latest Publications
- Open Access
- 31 January 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (3) , 1452
Microbiome Signatures in Advanced Gastric Cancer: Emerging Biomarkers for Risk Stratification, Therapy Guidance, and Prognostic Insight
Gastric cancer (GC), often diagnosed at advanced or metastatic stages, remains a significant clinical challenge requiring novel biomarkers for early detection, risk stratification, and effective, personalized treatment optimization. Emerging evidence underscores a strong association between gut microbiome dysbiosis and GC initiation, progression, and therapeutic outcomes. This review explores the potential of the advanced/metastatic gastric microbiome as a source of diagnostic and targetable biomarkers and its role in modulating responses to immunotherapy. Although Helicobacter pylori (H. pylori) is the most significant risk factor for GC, several other gastrointestinal taxa—including Fusobacterium nucleatum (F. nucleatum)—have been implicated in advanced GC (AGC). At its inception, microbial dysbiosis contributes to chronic inflammation and immune evasion, thereby influencing tumor behavior and treatment efficacy. Integrating microbiome-based biomarkers into risk stratification, GC staging, and targetable treatment frameworks may enhance early detection, inform immunotherapy strategies, and improve patient-specific treatment responses. Bifidobacterium and Lactobacillus rhamnosus GG have the potential to change the immunotherapy framework with their direct influence on dendritic cell (DC) and cytotoxic T cell (CTL) activity. However, clinical translation is impeded by methodological heterogeneity, causality limitations, and a lack of clinical trials. Nonetheless, the integration of microbiome profiling and the development of therapeutic microbiome modulation strategies, such as personalized probiotics regimens and fecal microbiota transplantation, hold substantial potential for improving clinical outcomes and reducing treatment-related toxicity in GC management.
- 31 January 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (3) , 1452
Open AccessMicrobiome Signatures in Advanced Gastric Cancer: Emerging Biomarkers for Risk Stratification, Therapy Guidance, and Prognostic Insight
Gastric cancer (GC), often diagnosed at advanced or metastatic stages, remains a significant clinical challenge requiring novel biomarkers for early detection, risk stratification, and effective, personalized treatment optimization. Emerging evidence underscores a strong association between gut microbiome dysbiosis and GC initiation, progression, and therapeutic outcomes. This review explores the potential of the advanced/metastatic gastric microbiome as a source of diagnostic and targetable biomarkers and its role in modulating responses to immunotherapy. Although Helicobacter pylori (H. pylori) is the most significant risk factor for GC, several other gastrointestinal taxa—including Fusobacterium nucleatum (F. nucleatum)—have been implicated in advanced GC (AGC). At its inception, microbial dysbiosis contributes to chronic inflammation and immune evasion, thereby influencing tumor behavior and treatment efficacy. Integrating microbiome-based biomarkers into risk stratification, GC staging, and targetable treatment frameworks may enhance early detection, inform immunotherapy strategies, and improve patient-specific treatment responses. Bifidobacterium and Lactobacillus rhamnosus GG have the potential to change the immunotherapy framework with their direct influence on dendritic cell (DC) and cytotoxic T cell (CTL) activity. However, clinical translation is impeded by methodological heterogeneity, causality limitations, and a lack of clinical trials. Nonetheless, the integration of microbiome profiling and the development of therapeutic microbiome modulation strategies, such as personalized probiotics regimens and fecal microbiota transplantation, hold substantial potential for improving clinical outcomes and reducing treatment-related toxicity in GC management.
- Open Access
- 13 May 2025
- Published by MDPI AG in Preprints.org
Microbiome Signatures in Gastric Cancer: Emerging Biomarkers for Risk Stratification, Therapy Guidance, and Prognostic Insight
Gastric cancer (GC), frequently diagnosed at advanced/metastatic stages, necessitates the identification of novel biomarkers for early detection and optimized treatment strategies. Emerging research suggests a strong association between gut microbiome alterations and GC development, progression, and therapeutic response. This study explores the potential of the gastric microbiome as a source of biomarkers to predict GC prognosis and progression, while also assessing its modulatory influence on first-line treatments for metastatic disease. Beyond Helicobacter pylori, other bacterial taxa such as Fusobacterium, Lactobacillus, and Peptostreptococcus have been implicated in carcinogenesis and immune modulation. Microbial dysbiosis is increasingly linked to chronic inflammation, immune evasion, and altered drug metabolism, which may influence tumor dynamics and therapeutic outcomes. Microbiome-based biomarkers offer promising avenues for early GC detection, particularly in H. pylori-negative cases, and may enhance response prediction to immunotherapies, including PD-1/PD-L1 inhibitors. However, critical challenges remain, including a lack of methodological standardization, confounding variables like diet and antibiotic use, and unresolved issues around causation versus correlation. Despite these hurdles, the integration of microbiome data with other omics platforms (e.g., transcriptomics, metabolomics, ctDNA) holds significant promise for refining predictive models. Furthermore, therapeutic modulation of the microbiome, via probiotics, fecal microbiota transplantation, or diet may offer novel strategies to enhance treatment efficacy and reduce toxicity in GC management.
- 13 May 2025
- Published by MDPI AG in Preprints.org
Open AccessMicrobiome Signatures in Gastric Cancer: Emerging Biomarkers for Risk Stratification, Therapy Guidance, and Prognostic Insight
Gastric cancer (GC), frequently diagnosed at advanced/metastatic stages, necessitates the identification of novel biomarkers for early detection and optimized treatment strategies. Emerging research suggests a strong association between gut microbiome alterations and GC development, progression, and therapeutic response. This study explores the potential of the gastric microbiome as a source of biomarkers to predict GC prognosis and progression, while also assessing its modulatory influence on first-line treatments for metastatic disease. Beyond Helicobacter pylori, other bacterial taxa such as Fusobacterium, Lactobacillus, and Peptostreptococcus have been implicated in carcinogenesis and immune modulation. Microbial dysbiosis is increasingly linked to chronic inflammation, immune evasion, and altered drug metabolism, which may influence tumor dynamics and therapeutic outcomes. Microbiome-based biomarkers offer promising avenues for early GC detection, particularly in H. pylori-negative cases, and may enhance response prediction to immunotherapies, including PD-1/PD-L1 inhibitors. However, critical challenges remain, including a lack of methodological standardization, confounding variables like diet and antibiotic use, and unresolved issues around causation versus correlation. Despite these hurdles, the integration of microbiome data with other omics platforms (e.g., transcriptomics, metabolomics, ctDNA) holds significant promise for refining predictive models. Furthermore, therapeutic modulation of the microbiome, via probiotics, fecal microbiota transplantation, or diet may offer novel strategies to enhance treatment efficacy and reduce toxicity in GC management.